Ovarian Cancer

Treatment with abemaciclib plus hormonal therapy showed promise in LGSOC/EEC but not in HGSOC, and larger studies are needed to validate these findings.

The median DOR with Rina-S was not reached and the treatment was well tolerated in patients with FRα-unselected platinum-resistant ovarian cancer.

Pamiparib plus surufatinib showed signals of activity with a largely hematologic adverse effect profile in patients with PARP-pretreated, platinum-resistant ovarian cancer.

The combination of avutometinib and defactinib produced durable responses in recurrent low-grade serous ovarian cancer.

The combination of pembrolizumab and lenvatinib showed promising activity including durable responses in patients with platinum-resistant HGSOC.

Frontline maintenance with niraparib and bevacizumab showed efficacy and safety profiles that are in line with similar regimens in advanced ovarian cancer.

Luveltamab tazevibulin was active and safe in patients with platinum-resistant ovarian cancer and a FRα expression of at least 25%.

Mirvetuximab soravtansine continued to showcase superior OS, PFS, ORR, & DOR benefits over chemotherapy in FRα-positive platinum-resistant ovarian cancer.

Patients with cyclin E1–positive platinum-resistant ovarian cancer experienced a greater response to azenosertib vs the overall DENALI population.

The KEYLYNK-001 trial found improved PFS among patients with advanced ovarian cancer given pembrolizumab/olaparib.

Afuresertib combined with paclitaxel did not elicit PFS or OS benefits vs paclitaxel alone in patients with unselected platinum-resistant ovarian cancer.

Kathleen N. Moore, MD, MS, discusses novel antibody-drug conjugates currently in development for patients with FRα-expressing ovarian cancer.

Emily M. Hinchcliff, MD, MPH, discusses the growing role of ADCs like mirvetuximab soravtansine for the treatment of patients with ovarian cancer.

SON-1010 is being investigated for its potential to improve outcomes in solid tumors.

The top 5 videos of the week cover insights in ovarian cancer, NSCLC, CSCC, follicular lymphoma, and CLL.

Stéphanie Lheureux, MD, PhD, discusses technological advancements in ovarian cancer that could optimize treatment delivery, timing, and sequencing.

Ritu Salani, MD, MBA, details the significance of trials examining avutometinib plus defactinib and enthusiasm for ADCs in ovarian cancer.

CUSP06 received fast track designation from the FDA for patients with platinum-resistant ovarian cancer.

Kathleen N. Moore, MD, MS, discusses ongoing trials of novel ADCs in ovarian cancer and the potential relevance of biomarker expression for these agents.

Kathleen N. Moore, MD, MS, details the March 2024 approval of mirvetuximab soravtansine for the treatment of FRα–positive ovarian cancer.

Floortje J. Backes, MD, discusses ongoing research to watch in ovarian cancer.

Floortje J. Backes, MD, discusses other potential roles for mirvetuximab soravtansine and other antibody-drug conjugates in ovarian cancer.

Floortje J. Backes, MD, discusses data for mirvetuximab soravtansine in FRα-positive, platinum-sensitive ovarian cancer

Floortje J. Backes, MD, discusses how to approach FRα testing in ovarian cancer.

Floortje J Backes, MD, discusses how mirvetuximab soravtansine has affected the management of platinum-resistant ovarian cancer.